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Abstract
Recently, there has been growing interest in the relationship between allergic and autoimmune diseases. Allergy
and autoimmunity can be considered two potential outcomes of dysregulated immunity and analysis of literature
data shows a strong positive association between a history of Th2-mediated allergic disorders and Th1-mediated
autoimmune disorders.
Autoimmune thyroid diseases are the most common of all autoimmune pathological conditions.
Currently, the mechanisms explaining an association among atopy, autoimmunity, and thyroid diseases are not fully
understood.
There are data in literature pointing to the relationship between melatonin and thyroid activity. Several studies
have suggested a paracrine role for this molecule in the regulation of thyroid activity, documenting that
administration, as an antioxidant, in thyroid tissues under conditions of increased oxidative stress, could be helpful
to reduce the oxidative processes involved in autoimmune thyroid diseases.
Although thyroid autoimmunity has been regularly associated with atopic conditions in children, the possible
protective role of melatonin has not yet been investigated.
This review summarizes what is known regarding the connection between atopy and autoimmune thyroid diseases,
and analyses the probable beneficial action of melatonin.
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Background
Hypersensitivity reactions of the immune system have
been categorized into atopic and autoimmune reactions,
depending on whether the antigen triggering the reaction
is endogenous or exogenous, types of cellular and humoral
components involved, and clinical symptoms [1].
Atopy is an individual or familial tendency to produce
IgE antibodies in response to low doses of allergens and
to develop typical symptoms such as atopic dermatitis,
allergic rhinitis, and asthma [2, 3]. Atopic diseases have
increased in frequency in recent decades and now affect
approximately 20 % of the population worldwide [4].
The risk of developing atopic diseases is complex and is
strongly influenced by both genetic and environmental
factors [5, 6].
Atopy and autoimmunity are two potential outcomes
of dysregulated immunity [7].
The incidence of autoimmune diseases has increased
in recent decades. Although these conditions have a
multifactorial pathogenesis, one generally accepted
model is that immune dysregulation, secondary to an
infectious process or excessive exposure to an inciting or
cross-reactive antigen, promotes a T helper (Th) 1
response leading to progressive inflammation and auto-
immunity. Reciprocal counter-regulation of Th1 and
Th2 cells predicts that Th1-type autoimmune disease
and Th2-mediated allergic disease would occur in mutu-
ally exclusive populations of patients [8].
However, data literature are controversial regarding
true associations between atopy and autoimmune
disease [9–12]. Recent observations have identified
additional lymphocyte subsets, such as Th17 cells [9],
soluble factors such as IL-9 [10] and regulatory T cells
(T reg) [11] as a common link between atopy and
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autoimmunity. It has been reported that infantile atopy
increases a predisposition to autoimmune disorders,
suggesting that these two entities might have immune
pathways, common to both pathological conditions, jus-
tifying partially the increased prevalence and/or the co-
presence of atopic and autoimmune diseases [13, 14].
Conversely, Skaaby et al. [12] did not find statistically
significant associations between atopic predisposition
and autoimmune disorders, although they could not ex-
clude moderate effects of atopy on autoimmune disease.
The thyroid gland is the most common organ affected
by autoimmune disease. Autoimmune phenomena, espe-
cially thyroid autoimmunity, have often been associated
with other autoimmune diseases, such as chronic urti-
caria in adults [15] and children [16].
Although thyroid autoimmunity has regularly been
associated with atopy in children, the possible protective
role of antioxidants, such as melatonin, has not yet been
fully investigated, although its role has been documented
in other atopic conditions, such as dermatitis and
asthma [17, 18].
Melatonin plays key roles in several important physio-
logical functions, including neuroimmunological actions
and immunomodulatory effects in allergic diseases, al-
though its potential use in atopic patients has rarely
been considered [19].
Experimental data [17] suggested that melatonin
inhibits development of atopic eczema, a condition ac-
companied by infiltration and activation of mast cells
with release vasoactive and proinflammatory mediators,
and reduces serum total IgE and IL-4.
Furthermore, emerging evidence suggest that mela-
tonin represents a potent antioxidant and protective
substance in skin photobiology [20, 21]. It has been re-
ported that melatonin also protects keratinocytes against
ultraviolet (UV) radiation B-induced oxidative stress and
DNA damage and that endogenous intracutaneous
melatonin production, together with topically-applied
exogenous melatonin, would represent one of the most
potent anti-oxidative defense systems against the UV-
induced damage to the skin [22].
Melatonin, therefore, has been hypothesized as a
potential therapeutic option also in atopic dermatitis
(AD), protecting skin integrity and helping to maintain a
functional epidermal barrier [23, 24].
Moreover, it has been documented that melatonin,
regulating smooth muscle tone and influencing the im-
mune response in allergic asthma, could be implicated
in regulating bronchial hyper-responsiveness [25, 26].
Furthermore, melatonin may, however, act as a pro-
inflammatory agent in asthma leading to bronchial
constriction [17, 25].
There are some data in literature pointing to the
relationship between melatonin and thyroid activity
and its involvement in the hypothalamic-pituitary-
thyroid axis [27].
This review summarizes what is known regarding
the connection between atopy and autoimmune thy-
roid diseases and analyses the possible protective role
of melatonin.
A link between atopy and autoimmune thyroid disease
It has been proposed that innate immunity has a role
in allergic inflammation, and epithelial cells, dendritic
cells, natural killer lymphocytes, and mast cells might
play a regulatory role in allergy. It has also been
suggested that there is some form of cooperation
between Th2 mediated allergy, and Th1 mediated in-
flammation responses [28].
The adaptive cellular immune response has been char-
acterized broadly as being polarized in two directions
[29]. Type 1 responses, directed by Th1 CD4+ T cells
and identified by the signature cytokine interferon
(IFN)-g, are considered as protective against infections
by intracellular pathogens [30], and have been incrimi-
nated in the pathogenesis of autoimmune diseases, such
as thyroid disease. Many other autoimmune diseases
such as rheumatoid arthritis, juvenile rheumatoid arth-
ritis, insulin-dependent diabetes mellitus and multiple
sclerosis are associated with a Th1 phenotype [31].
Autoimmune thyroid disease (ATD) is a multifactorial
disease in which autoimmunity against thyroid antigens
develops against a particular genetic background facili-
tated by exposure to environmental factors. Auto-
immune thyroid diseases are characterized by infiltration
of the thyroid by T and B cells which are reactive to thy-
roid antigens, by the production of thyroid autoanti-
bodies and by abnormal thyroid function [32]. ATD
presents a hereditary component, as reported in several
studies that show a definite genetic propensity for
thyroid autoimmunity to run in families [33]. The child-
hood prevalence of chronic autoimmune thyroiditis
peaks in early to mid-puberty [34].
By contrast, type 2 responses, directed by Th2 CD4+
T cells and identified by the signature cytokines interleu-
kin (IL) -4, IL-5 and IL-13, are considered to play a
pathogenic role in allergic diseases [35]. Reciprocal
counter-regulation of Th1 and Th2 cells [36] predicts
that Th1-type autoimmune diseases and Th2-mediated
allergic diseases would occur in mutually exclusive pop-
ulations of patients. However, recent observations have
challenged the validity of the long-standing Th1/Th2
paradigm [37], and a far more complex story explaining
the immunological basis of cellular immune-mediated
host defence and the pathogenesis of autoimmune and
allergic diseases is emerging. The new paradigm identi-
fies additional lymphocyte subsets, such as Th17 T cells,
Treg and novel soluble factors. These provide a new
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prism through which to examine the intersection of
autoimmune and allergic disease (Fig. 1) [37].
Mittermann et al. demonstrated that a considerable
percentage of patients suffering from atopic dermatitis
had enhanced IgE autoantibody levels against a broad
variety of human proteins expressed in a variety of cell
and tissue types. Furthermore, they showed that the
levels of IgE autoantibodies were associated with severity
of disease [38].
Several studies reported a higher incidence of ATD in
subjects affected by allergic diseases. Pedullá et al.
showed an increased prevalence of thyroid autoimmun-
ity in children with AD, underlining a significant rela-
tionship between the expression of AD and thyroid
autoimmunity in a pediatric population [39]. Further-
more, Pedullá et al. demonstrated that the frequency of
thyroid autoimmunity was significantly higher among
children with IgE-mediated AD than non-IgE-mediated
AD, suggesting atopy and thyroid autoimmunity as po-
tential outcomes of dysregulated immunity [39]. Hidaka
et al. suggested that eosinophils and their activation play
an important role in inflammatory processes in allergic
diseases. Th2 cytokines stimulate eosinophils and it has
recently been found that the peripheral eosinophil count
was increased in thyrotoxic patients with Graves’ disease
[40]. Moreover, the same authors demonstrated that an
allergic condition is closely related to Graves’ disease
and that a Th2-type immune response is crucial in the
pathogenesis of Graves’ disease [41].
Use of antioxidants in thyroid diseases: melatonin
Whereas oxidative reactions occur in all tissues and
organs, the thyroid gland is an organ in which oxidative
processes are widely signalized and are indispensable for
physiological functions of the organism [42]. Hydrogen
peroxide acts as an electron acceptor at each step of thy-
roid hormone biosynthesis and is essential for thyroper-
oxidase (TPO) activity, the key enzyme in this process.
In addition, antioxidative enzyme activity [superoxide
dismutase (SOD), glutathione (GSH) peroxidase (GSH-
Px) and catalase (CAT)] has been well documented in
the thyroid [43].
Fig. 1 Th1 - Th2 - Th17 response and respective cytotoxic and humoral involvement in inflammation and autoimmunity
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The use of various exogenous antioxidants in thyroid
tissues has been shown to be beneficial in experimental
(in vitro or in vivo) studies [43, 44]. Unfortunately, the ap-
plicability of different antioxidants has not yet been clearly
confirmed in clinical studies and still no effective antioxi-
dative medication is available for widespread use [45].
Moreover, melatonin, an ubiquitous antioxidant mol-
ecule with pleiotropic action in many tissues, has protect-
ive effects against oxidative stress [46, 47], the thyroid
included [48].
There are data in literature pointing to the relationship
between melatonin and thyroid activity. Several studies
have suggested a paracrine role for this molecule in the
regulation of thyroid activity. The antioxidant role of
melatonin in the thyroid gland was first reported by
Kvetnoy [49]. It has been demonstrated that melatonin
is, at rat thyroid level, synthesized by C cells -the minor
neuroendocrine thyroid cell population- and, that mela-
tonin receptors (MT)1 are present in follicular cells [50],
suggesting a role for thyroid melatonin. Recently, an-
other study has shown that thyroid C-cells synthesize
melatonin under thyroid-stimulating hormone control,
supporting the hypothesis of a paracrine role for C-cell-
synthesised melatonin within the thyroid gland.
In particular, Garcia-Marin et al. [27] analyzed both the
effect of melatonin on the expression of the thyroid
tissue-specific genes PAX8 and TTF1 and examined TSH
regulation of key enzymes for melatonin biosynthesis,
such as aralkylamine N-acetyltransferase (AANAT) and
acetyl serotonin methyltransferase (ASMT). They showed
both the involvement of melatonin in thyroid function by
directly-regulating thyroglobulin gene expression in fol-
licular cells and that AANAT and ASMT are regulated by
thyroid-stimulating hormone. Furthermore, it has been
demonstrated that thyroid C-cells synthesized melatonin
under thyroid-stimulating hormone control, supporting
the possible paracrine role for C-cell-synthesised mela-
tonin within the thyroid [27].
Additionally, Karbownik M. et al. commented the
evidence that melatonin, acting as an antioxidant agent,
influences thyroid growth, counteracting significant oxida-
tive damage that occurs in the course of thyroid diseases,
and the stimulatory effects of thyroid hormones [42].
The same research group [48], in an experimental
study, estimated melatonin effects on basal and iron-
induced lipid peroxidation related to Fenton reaction in
homogenates of the porcine thyroid gland, showing that
the degree of lipid peroxidation was decreased, in a
concentration-dependent manner, by melatonin, and
supporting the protective role of this indolamine in pre-
venting pathological processes, such as thyroid cancer,
related to oxidative injury.
Data in literature has shown melatonin action on the
thyroid gland itself, such as the inhibitory effect of
melatonin on cell proliferation and thyroid hormone
synthesis [51, 52] or the protective effect of melatonin
against oxidative damage in the thyroid gland [53, 54].
It has been well reported that the administration of
chronic melatonin is efficient in protecting against the
damaging effects of different prooxidants and that under
basal conditions it does not change the level of oxidative
damage to macromolecules [55]. In addition, it has been
evaluated that the effects of Caffeic acid phenethyl ester
(CAPE) on Fenton reaction-induced oxidative damage to
membrane lipids (lipid peroxidation, LPO) in porcine
thyroid and the liver are similar to those caused by
melatonin. Whereas CAPE decreased basal LPO in a
concentration-dependent manner in both tissues, mela-
tonin did not change the basal LPO level. When antioxi-
dants were used together with Fenton reaction substrates,
they prevented – in a concentration-dependent manner
and to a similar extent – experimentally- induced LPO in
both tissue effects of melatonin [56].
Conclusions
Regulatory T cells are important components of the
homeostasis of the immune system, as impaired regula-
tory T cell activity can cause autoimmune diseases and
atopy [57].
Atopy and autoimmunity are manifestations of
immune system dysfunction and are referred to as dis-
tinct immunological reactions with common pathogenic
mechanisms [58].
The mechanism whereby ATD is associated with aller-
gic diseases is poorly understood. Several researchers
have observed serum histamine releasing activity in a
subgroup of adult patients with chronic urticaria, which
was attributable to an IgG autoantibody directed against
the alpha chain of the high affinity IgE receptor of the
mast cells or, less commonly, against IgE itself [59, 60].
Rottem M. et al. [61] affirmed that atopic skin mani-
festations and thyroid autoimmunity “most likely are as-
sociated, parallel autoimmune events,” whereas Dreskin
SC. et al. concluded that [62] “there are no compelling
arguments to decide whether or not thyroid auto-
immunity plays a significant role in the pathogenesis of
chronic urticaria.”
It is important to identify infants at risk for developing
lifelong chronic atopic and autoimmune diseases and
utilize the critical window of opportunity early in life for
therapeutic intervention that targets Th1- or Th2-specific
responses revealing atopy or autoimmunity respectively.
During the last decade, wide evidence has contributed
to confirm the antioxidant and protective role played by
melatonin in the normal, as well as in the prooxidant-
agent insulted, thyroid-gland [43, 48, 63].
Finally, it has been documented that the administra-
tion of melatonin, as an antioxidant, in thyroid tissue
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under condition of increased oxidative stress, could be
helpful to reduce oxidative processes involved in auto-
immune thyroid diseases [27, 42, 48].
Melatonin is a molecule with an excellent biosafety
profile, widely used for decades in some countries, and
no serious side effects or treatment-related complica-
tions with short or long-term melatonin therapy in
children and adults have been reported [64].
In addition, further studies are necessary to elucidate
the underlying mechanisms and the common pathways
involved in atopy and thyroid autoimmune diseases.
Therefore, melatonin could be hypothesized as a poten-
tially useful agent in the treatment of ATD, but further
studies are necessary to clarify the immunological-
hormonal effects of this indolamine.
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